Irmela Mantel Selected Research

Atrophy

7/2022	Automated foveal location detection on spectral-domain optical coherence tomography in geographic atrophy patients.
11/2021	Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography.
11/2021	Personalized Atrophy Risk Mapping in Age-Related Macular Degeneration.
5/2019	MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
1/2019	Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.
11/2011	Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Irmela Mantel Research Topics

Disease

33	Macular Degeneration (Age-Related Maculopathy) 01/2024 - 01/2007
7	Central Serous Chorioretinopathy 09/2023 - 09/2010
6	Atrophy 07/2022 - 11/2011
4	Choroidal Neovascularization 01/2019 - 03/2009
3	Inflammation (Inflammations) 12/2023 - 01/2014
2	Retinal Detachment (Retinal Detachments) 10/2022 - 10/2014
2	Neoplasms (Cancer) 12/2015 - 10/2014
1	Refractive Errors (Refractive Error) 03/2023
1	COVID-19 01/2022
1	Weight Loss (Weight Reduction) 01/2020
1	Vision Disorders (Hemeralopia) 01/2019
1	Pain (Aches) 01/2018
1	Telangiectasis (Telangiectasia) 12/2017
1	Paraneoplastic Syndromes (Paraneoplastic Syndrome) 12/2015
1	Toxic Optic Neuropathy 12/2015
1	Ischemia 10/2014
1	Uveal melanoma 10/2014
1	Endophthalmitis (Ophthalmia) 01/2014
1	Cysts 03/2013
1	Hemorrhage 11/2011
1	Fibrosis (Cirrhosis) 11/2011
1	Eye Diseases (Eye Disease) 01/2010
1	Idiopathic Juxtafoveal Retinal Telangiectasia 11/2009
1	Myopia 03/2009

Drug/Important Bio-Agent (IBA)

20	Ranibizumab (Lucentis)FDA Link 08/2020 - 01/2008
19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2024 - 01/2007
11	afliberceptIBA 08/2020 - 10/2015
9	Retinaldehyde (Retinal)IBA 03/2023 - 09/2009
3	Retinal Pigments (Pigments, Visual)IBA 11/2021 - 11/2011
2	Biomarkers (Surrogate Marker)IBA 09/2023 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 09/2023 - 01/2020
2	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2023 - 04/2019
2	Endothelial Growth FactorsIBA 09/2018 - 01/2010
1	Indicators and Reagents (Reagents)IBA 01/2024
1	Dexamethasone (Maxidex)FDA LinkGeneric 12/2023
1	SteroidsIBA 12/2023
1	C-Reactive ProteinIBA 09/2023
1	PTX3 proteinIBA 09/2023
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 09/2023
1	GlucocorticoidsIBA 09/2023
1	Vascular Endothelial Growth FactorsIBA 01/2020
1	Fluorescein (Funduscein)FDA LinkGeneric 04/2019
1	Mineralocorticoid Receptor AntagonistsIBA 01/2019
1	Antidepressive Agents (Antidepressants)IBA 01/2019
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2019
1	AntibodiesIBA 12/2015
1	AntigensIBA 12/2015
1	Bevacizumab (Avastin)FDA Link 10/2014
1	Complement Factor B (Factor B)IBA 03/2014
1	Complement System Proteins (Complement)IBA 03/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2014

Therapy/Procedure

9	Intravitreal Injections 01/2024 - 03/2009
5	Therapeutics 12/2023 - 01/2010
5	Injections 03/2022 - 01/2007
4	Retreatment 01/2019 - 03/2013
1	Aftercare (After-Treatment) 10/2022
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2020
1	Radiotherapy 12/2015
1	Proton Therapy 10/2014
1	Lasers (Laser) 10/2014
1	Light Coagulation 10/2014